Clinical Trial Update: Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) [Phase 4]

View source ↗

Summary

Phase 4 study updating apixaban use in atrial fibrillation patients undergoing cardioversion; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Eliquis (apixaban)

Snippet

Sponsor: Pfizer | Conditions: Atrial Fibrillation | Phase 4 | Status: COMPLETED | Results posted: 2018-04-10